載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$55.25
+US$0.04 · +0.07%
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
收盤時
US$55.25
+US$0.04 · +0.07%
盤後
US$55.50
+US$0.25 · +0.45%
10月12日 下午7:07 ET
盤中時間採用ET。市場資料可能有所延遲。
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
日內區間
目前US$55.25
52週區間
目前US$55.25
盤中時間採用ET。市場資料可能有所延遲。
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
日內區間
目前US$55.25
52週區間
目前US$55.25
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$66.67
上漲空間 20.67%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4212.55萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM3846.87萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1655.32萬0.02%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1362.26萬0.10%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO927.51萬0.05%180億 USD0.06%US$112.27-0.35%
First Trust Small Cap Growth AlphaDEX FundFYC917.07萬0.68%13.49億 USD0.70%US$114.85-0.44%
State Street SPDR S&P Pharmaceuticals ETFXPH866.13萬1.88%4.62億 USD0.35%US$64.01-0.99%
Schwab U.S. Small-Cap ETFSCHA792.68萬0.04%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFirst Trust Small Cap Growth AlphaDEX FundFYCState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
